Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.

PloS one - 1 Jan 2013

d'Abramo Cristina, Acker Christopher M, Jimenez Heidy T, Davies Peter

Abstract excerpt

The use of antibodies to treat neurodegenerative diseases has undergone rapid development in the past decade. To date, immunotherapeutic approaches to Alzheimer's disease have mostly targeted amyloid beta as it is a secreted protein that can be found in plasma and CSF and is consequently accessib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibody Affinity
Share to Antibody Specificity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CA1 Region, Hippocampal

Share to Immunization, Passive

Share to Prosencephalon

Share to tau Proteins

Share to Tauopathies

Source

Open in PubMed Open full text

Identifiers

PMID: 23638068
DOI: 10.1371/journal.pone.0062402
PMCID: PMC3639259

Genes

PHF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23638068-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.PMID 23638068Read ↗

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy ModelsSemantic proximity Read ↗

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.Semantic proximity Read ↗

Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.Semantic proximity Read ↗

Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic miceSemantic proximity Read ↗

Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.Semantic proximity Read ↗

AAV-mediated peripheral single chain variable fragments’ administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapySemantic proximity Read ↗

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific AntibodiesSemantic proximity Read ↗

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencySemantic proximity Read ↗

Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody FunctionsSemantic proximity Read ↗

Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.Semantic proximity Read ↗

Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS.Semantic proximity Read ↗

Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.